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Context:Orexins A andB are neuropeptides that bind and activate 2 types of receptors. In addition
to direct action in the brain, the orexinergic system has broader implications in peripheral organs,
and it has been proposed to have a role in the induction of apoptosis. There are very few data on
the endometrium.
Objective: The expression and epigenetic regulation of type 2 orexin receptor (OX2R) was inves-
tigated in the human endometrium as well as in endometrial endometrioid carcinoma (EEC).
Methods:OX2R localization was studied by immunohistochemistry in normal endometrium (n 24)
and in EEC (n 32). The DNAmethylation status of a CpG island located in the first exon ofOX2Rwas
analyzed by bisulfite sequencing in normal (n 18), EEC (n 34), and 3 endometrial cell lines. On the
latter,mRNAexpressionandWesternblottingaswellas invitro inductionwithorexinwereperformed.
Results: Expressionof theOX2Rproteinwasdetected innormal endometrial epithelia,whereas itwas
frequently lacking inEEC.This losswasassociatedwithhypermethylationofOX2R inEEC incomparison
withnormalendometrium(medianCpGmethylationpercentagesof48.85%and5.85%, respectively).
In cell lines, hypermethylation correlatedwithweakOX2Rexpression. Additionally, in vitro treatment
of the 3 EEC cell lines with orexins A and B did not result in proliferation change
Conclusions:Altogetherourdataprovideevidence for theepigenetic silencingofOX2R in EEC. The
implication of the OX2R loss in tumoral progression remains to be elucidated. (J Clin Endocrinol
Metab 98: 1549–1557, 2013)
The orexins, also known as hypocretins, are 2 neuro-peptides, orexin A (OX A) and B (OX B), processed
from a common precursor by proteolytic cleavage (1).
Orexins bind to and activate 2 types of serpentine G-cou-
pled receptors, type 1 and type 2 receptors (OX1R and
OX2R) with different affinity. OX1R is highly selective
for OX A, whereas OX2R is a nonselective receptor that
binds both OX A and OX B (2). Although initially de-
scribed as neuropeptides involved in the regulation of
feeding behavior and localized in the hypothalamus, the
orexins are now considered to have a broader action in
peripheral tissues, and several groups have demonstrated
their involvement in a number of physiological processes
(reviewed in Reference 3). In the gastrointestinal tract,
orexins have been found to regulate not only the gastric,
intestinal, and pancreatic secretions but also gut motility
(4). In the rat (5, 6) and human (7), the testis holds prob-
ably the second highest local orexin concentration after
the brain (8), and it is speculated that orexins might act in
an autocrine/paracrine manner (7). In the rat ovary, a
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strong up-regulation of both OX1R and OX2R was re-
ported during proestrus togetherwith a similar increase in
the hypothalamus and pituitary, suggesting an involve-
ment of orexins in ovulation (9).
The orexinergic system has also been proposed to have
implication in the induction of apoptosis (reviewed inRef-
erence 10). Notably the OX1R seems to mediate the ap-
optosis induced by both OXA andOX B in vitro in colon
cancer cell lines (11), leading to the proposal of OX1R as
a therapeutic target in cancer therapy (10).
Concerning endometrium and endometrial cancer,
very few data exist, and to our knowledge, only the ab-
sence of OX A immunohistochemical reactivity has been
reported in the human endometrium (12). Endometrial
carcinoma is a hormone-related cancer that is the most
common gynecological malignancy in theWestern world,
affecting on average 15–20 women of 100 000 per year.
Based on clinical-pathological and molecular characteris-
tics, a clear dichotomy can be drawn along 2 distinct path-
ways. The first is type I estrogen-dependent endometrial
endometrioid carcinoma (EEC), which represents the vast
majority of cases, and the second is type II, which includes
high-grade papillary serous and clear cell carcinomas.
EEC has a general favorable outcome and is often asso-
ciated with a clinical history of unopposed estrogen ex-
posure. However, although great progress has been re-
corded recently in the understanding of genetic events
during cancer progression (reviewed in Reference 13), the
molecular pathogenesis of these cancers remains poorly
understood.Deregulationof gene expression is a hallmark
of cancer. It is now recognized that in addition to genetics,
aberrant epigenetic modifications play a major role in the
tumorigenic process (14).
DNA methylation is the most studied epigenetic mod-
ification, and hypermethylation of CpG islandswithin the
regulatory region of tumor suppressor genes has been in-
creasingly described for endometrial cancer (reviewed in
Reference 15). This event has been shown to contribute in
the silencing of the corresponding gene and may confer a
growth advantage for tumor cells in many cancers (16,
17). Distinct patterns of DNA methylation among differ-
ent tumors are now used as signature for diagnosis and
prognosis (18). For the determination of methylation in-
tensities, the gold standard is the bisulfite sequencing after
bacterial cloning, which allows precise and quantitative
mapping of CpG sites in individual alleles (19).
In the current study, the loss of OX2R protein in a
cohort of 34 EECs as compared with 18 normal endome-
trium samples was shown to be associated with the hy-
permethylation of the first exon of OX2R. To shed light
on the implications of the OX2R silencing in the context
of endometrial carcinogenesis, 3 endometrial cell lines
were induced with graded concentrations of orexins.
Materials and Methods
Endometrial tissues
Endometrial cancer samples were collected from 34 patients
who underwent hysterectomy. The study was approved by the
Ethical Committee of University of Liege. Each cancer sample
was staged and graded by routine pathology analysis according
to usual methods and type I endometrioid cancer (EEC) were
selected for subsequent analysis. EEC lesions were subdivided
into grade 1, 2, and 3. Grading was done independently by 2
pathologists, and discordances were discussed until consensus
was reached. Cancer tissue was obtained by macroscopic dis-
section of the lesion and homogenous cancer tissue was selected,
avoiding necrotic regions that may be present in some cases.
Normal endometrial glands were obtained from premenopausal
(n8)ormenopausal (n10)women (meanage48years, range
32–75 years) by curettage with Novak curette. For premeno-
pausalwomen, normal endometrial tissueswere collectedduring
routine exploratory biopsy, regardless of the menstrual cycle.
Additionally, a panel of 24 control endometrium representative
of the completemenstrual cycle andmenopausal statuswas used
to establish the distribution of OX2R.
Immunohistochemical staining for the OX2R
antigen on formalin-fixed, paraffin-embedded
sections
After dewaxing in xylene, sections were pressure cooked for
1 minute in citrate buffer (pH 6.0) and incubated overnight at
4°C with 1:100 dilution of antibody MAB 52461 (R&D Sys-
tems, Europe, Ltd, Abington, United Kingdom). Detection was
performedwith biotinylated goat antimouse IgG (E0433, 1:400;
DakoCytomation, Glostrup, Denmark) followed by streptavi-
din/horseradish peroxidase (P0397, 1: 500; DakoCytomation).
Staining was done with 3–3-diaminobenzidine hydrochloride
(K3468, DakoCytomation) as chromogen and hematoxylin as
counterstain. Negative controls were performed by both omit-
ting the primary antibody and incubating the sections with non-
specific IgG. The specificity of MAB 52461 in this protocol was
verifiedoncontrolhuman testis tissueonwhicha labeling limited
to Leydig cells was obtained as previously described (7).
Cancer cell lines and DNA extraction
Human cell lines, ECC-1, Ishikawa, andMFE-280were from
the European Collection of Cell Cultures and were purchased
from Sigma-Aldrich (Health Protection Agency Culture Collec-
tions, Salisbury UK) and cultured at low passages. ECC-1 and
Ishikawa cell lines are derived fromwell-differentiated EEC and
are often chosen as models of endometrial epithelium in vitro
(20). By contrast, the MFE-280 cell line is derived from a recur-
rent poorly differentiated endometrial carcinoma and, although
being nearly diploid, represents a more advanced cancer grade
(21). All cell lines were grown in MEM (Gibco, Carlsbad, Cal-
ifornia) supplemented by 5% or 10% fetal calf serum as recom-
mended by the supplier. DNA from frozen endometrial tissue
and cell lineswas isolated using a PuregeneDNApurification kit
(QIAGEN, Hilden, Germany) according to the supplier’s rec-
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ommendation. The DNA concentration was determined with a
spectrophotometer (NanoDrop Technologies Inc, Wilmington,
Delaware), and the quality was assessed by agarose gel
electrophoresis.
Methylation data validation by bisulfite
sequencing
A bisulfite modification-based genomic sequencing was used
to establish a detailedmapping of theDNAmethylation pattern.
Control and cancer DNA (1g permodification) was treated by
bisulfite conversion (Methyl Easy kit;HumanGenetic Signature,
Sydney, Australia). Following PCRamplifications using 2 sets of
primers for the proximal (RCTCAATACTACAAACTC-
CTCTCC and GTGTTGGAATGAGGAGTAATTGAG) or dis-
tal regions (CTCTTTAAAACCTTCTCAACC and GGAGTT-
GAATGAAATTTAAGAGTTTTTT), fragments were cloned
into pJET 1.2 vector (Fermentas, Burlington, Canada), and ran-
dom colonies were screened for the correct amplicon via colony
PCR. Aminimum of 6 colonies per samples were sequenced (Big
Dye terminator cycle sequencing; Applied Biosystems, Foster
City, California) and analyzed using the BISMA web site (22)
Reverse transcription-polymerase chain reaction
Total RNA was extracted from cells pellets using a NucleoS-
pin RNA kit (Macherey-Nagel, Düren, Germany) following the
manufacturer’s instructions. Five micrograms of total RNAwas
reverse transcribed and oligo (deoxythymidine) primers and re-
verse transcriptase (Amersham, Little Chalford, Buckingham-
shire, United Kingdom). Five percent of the cDNAmixture were
amplified using OX2R sense primer (GTCGCAACTGGT-
CATCTGCT) and OX2R antisense primer (CGTCCTCAT-
GTGGTGGTTCT). Each of the 35 cycles of amplification con-
sisted of 1minute at 94°C, 30 seconds at 65°C, and 45 seconds
at 72°C. Amplicons were separated by electrophoresis in
1.8% agarose gel and viewed under UV illumination.
Similarly, a glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) transcript was amplified using specific primers
(sense, TGATGACATCAAGAAGGTGGTGAAG, and re-
verse, TCCTTGGAGGCCATGTGGGCCAT).
Western blotting
Protein lysates were run on a Laemmli 10% bis tris gel under
reducing conditions for 90minutes at 100 V. Separated proteins
were blotted onto polyvinyl difluoride membranes (GE Health-
care, Uppsala, Sweden) for 60 minutes (100 V) and blocked 1
hour in 5%milk/PBS. Primary antibody againstOX2R (ab3094,
1:500, overnight at 4°C; Millipore, Bellerica, Massachusetts)
was followed by antirabbit secondary antibody (Amersham).
Blots were developed using an ECL PlusWestern blotting detec-
tion system (GE Healthcare) and detected with ECL hyperfilm.
After a stripping step, the same blot was assayed with anti-
GAPDH antibody (Amersham) using the same method.
Cell proliferation and apoptosis assays
Cells were plated in a 96-well tissue culture plate (625, 1250,
or 2500 cells/well) containing OX A or OX B (Polypeptide Lab-
oratories, Strasbourg, France) at concentrations of 106, 107,
or 108 M. A cell proliferation test was performed after 24, 48,
and 72 hours using the WST1 kit as described by the manufac-
turer (Roche Diagnostics GmbH, Mannheim, Germany). The
experimentwas repeatedat least 3 times induplicate.Tomonitor
the apoptosis in the same culture conditions, a caspase-3/7 assay
was used according to the supplier’s recommendation (ApoTox-
Glo; Promega BioSciences, Madison, Wisconsin).
Statistical analysis
We assessed the statistical differences between different ex-
perimental groups using aMann-Whitney test. AP .05 (*)was
considered as significant. The statistical analyses were carried
out using the Prism 5.0 software (GraphPad, San Diego, Cali-
fornia) (*P  .05; **P  .01).
Results
The expression pattern of OX2R protein was first inves-
tigated in normal cycling endometrium by immunohisto-
chemistry (IHC) using an anti-OX2R monoclonal anti-
body. We tested a panel of 24 normal endometrial tissues
fromuntreatedwomen covering the entiremenstrual cycle
as well as postmenopausal endometrium. An intense to
moderate immunoreactivity with an OX2R antibody was
found in glandular cells. The most intense staining was
detected in the premenopausal secretory phase as well as
in the menopausal condition (Figure 1A and Table 1). By
contrast, when theOX2R antibodywas applied on the 32
EEC cases collected for this study (Table 2), 21 samples
(65.6% of the total) obtained an IHC score 0 correspond-
ing to an absence of staining either complete either with
minor area of labeling, which often localized close to the
interfacewith themyometrium (Figure1,BandC). For the
remaining 11 cases of EEC (34.4%of the total), a weak or
moderate immunostaining was recorded on the tumoral
tissue (IHC scores 1 or 2, Figure 1D).
To explain the frequent loss ofOX2R immunostaining,
the methylation status of the CpG island located in exon
1 of the OX2R gene was evaluated on 32 EEC samples
tested on IHC and on 18 controls endometria using bisul-
fite sequencing. Figure 2A shows the sequence of OX2R
exon 1 locus with the localization of the 27 CpG sites
investigated (14 in the proximal portion and 13 in the
distal portion). Twodifferent PCRswere used to cover the
whole exon 1 locus (proximal and distal portion) with the
exceptionof 90nucleotides comprising6CpGsites.Those
90 nucleotides were excluded for technical reasons (in-
ability to successfully amplify these regions by PCR).
Representative bisulfite sequencing charts of individual
CpG sites located onOX2R exon 1 are displayed in Figure
2, B and C, for patient 119 (grade 1) and control 15. The
complete bisulfite sequencing data for EEC and controls
samples are available in Supplemental Figures 1 and 2,
respectively, published on The Endocrine Society’s Jour-
nals Online web site at http://jcem.endojournals.org. Ta-
ble 2 and Figure 3A display the percentages of methylated
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CpG sites. Cancer and control samples were significantly
different using this parameter, with median values of
48.85% and 5.85%, respectively (P  .0001, Table 3). In
Figure 3B, methylation percentages are plotted against IHC
scores, showing the apparent lack of direct correlation be-
tweentheseparameters (Spearmanr0.3169,P .0772).
Additionally, to improve the reporting of bisulfite se-
quencing data, each clone was classified into 1 of the 3
methylation categories as defined by the Human Epig-
enome Project criteria (19): unmethylated (20% meth-
ylated CpGs), partially methylated (20%–80% methyl-
ation), and hypermethylated (80%methylation). Table
3 summarizes themedian values of frequency by themeth-
ylation categories for the controls
and EEC, showing again significant
differences (P  .0001). Figure 3,
C–G, show bisulfite sequencing data
allocated into the 3 methylation cat-
egories for each control woman (3C)
and each EEC patient (grades 1–3,
Figure 3, D–F). The results summa-
rized as mean values in Figure 3G
show comparable values for the 3
methylations categories for grades 1
and 2 EEC and a tendency toward
less hypermethylated clones in grade
3, although not statistically signifi-
cant because of a low inclusion of
grade 3 EEC (n  3).
Next, the methylation of the first
exon ofOX2R genewas assayed in 3
endometrial cell lines of epithelial
lineage (Figure 2D). In Ishikawa
cells, bisulfite sequencing revealed
sparse methylation thorough the
exon1exceptonCpGsites11and12
from the proximal region, which
were heavily methylated. By con-
trast, clones from the ECC-1 cell line
were hypermethylated. In MFE280,
both completely methylated and un-
methylated clones were recorded,
but the analysis of the sequence of
these clones (data not shown) did not allow the distinction
between thepaternal and thematernal alleles by themeans
of any nucleotide polymorphism. The transcription of the
OX2R genewas evaluatedbyRT-PCRand thepresenceof
OX2R protein byWestern blotting in the 3 cell lines (Fig-
ure 2, E and F). By RT-PCR, MFE280 cells displayed the
highest mRNA expression levels, whereas OX2R mRNA
was weak in Ishikawa cells and virtually absent in ECC-1
cells. The Western blotting analysis confirmed the pres-
enceofOX2Rprotein inMFE280cells by revealingaband
at 38 kDa as reported (23) and a weaker signal for
Ishikawa and ECC-1 cells.
The proliferation of the 3 cell lines upon OX A or OX
B inductionwas assessedwith theWST1 assay. Using var-
ious experimental conditions for cell culture and induc-
tion (data not shown), the supplementation of the cell
culture medium with OX A or OX B had no effect on the
proliferation of the 3 cell lines (concentrations of 108, 107,
and106Mforan incubationperiodof24,48,or72hours).A
representative set of data generated with the WST1 assay is
shown in Figure 2G in which the 3 cell lines were induced for
48hwithOXAandOXB.Similardata showingnodifference
Figure 1. Representative IHC of OX2R staining in control endometrium (A) and EEC (B–D). A, In
normal secretory endometrium, glands are intensely stained. B, No staining was detected in
grade 1 EEC (case 104, IHC score 0). C, Grade 2 EEC in which a focal zone localized close to the
myometrium is showing weak diffuse staining, whereas most the carcinoma was characterized
by an absence of staining (case 130, IHC score 0). D, Moderate staining in grade 2 EEC (case
124, IHC score 2). Scale bar is 100 m.
Table 1. IHC of OX2R in Normal Endometrium
Glands Stroma
Premenopausal
proliferative
 
Premenopausal
secretory
  or focally 
Menopausal  
, negative; , moderate; , intense.
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betweentreatedanduntreatedhavebeencollectedatothertime
points (24 hours, 72 hours, etc). To further evaluate the apo-
ptosis in the same culture conditions, a caspase-3/7 assay was
used. No evidence of apoptosis was demonstrated after 48
hours of induction with OXA orOXB (Figure 2H).
Discussion
Discovered 15 years ago, the orexinergic system has at-
tracted major interest with now more than 2500 publica-
tions recorded in PubMed web site with the keyword
orexin. First analyzed in the brain, the orexins and orexin
Table 2. Clinical Features, Methylation Status of OX2R, and IHC Scores for Controls (n  18) and EEC Patients
Listed Separately After the Pathological Grade: Grade 1 (n  21); Grade 2 ( n  10); Grade 3 (n  3)
Case
Number Menopause
Age,
y
Methylation,
%
IHC
Score
Controls 1 No 40 3.4 ND
2 No 48 7.9 ND
3 No 40 4.8 ND
4 No 37 2.6 ND
5 No 42 10.9 ND
6 No 39 2.7 ND
7 No 38 5.9 ND
8 No 32 7.2 ND
9 Yes 52 7.5 ND
10 Yes 54 5.8 ND
11 Yes 55 16.7 ND
12 Yes 50 10.7 ND
13 Yes 50 5.3 ND
14 Yes 54 2.2 ND
15 Yes 54 5.5 ND
16 Yes 49 5.9 ND
17 Yes 75 4.7 ND
18 Yes 54 7.3 ND
EEC grade 1 101 Yes 60 50.0 1
102 Yes 78 10.9 1
103 Yes 54 47.7 1
104 Yes 69 67.1 0
105 Yes 60 38.7 1
106 Yes 81 80.9 0
107 Yes 74 35.2 0
108 Yes 65 43.2 0
109 Yes 58 25.4 1
110 Yes 68 13.4 0
111 Yes 78 32.2 0
112 Yes 80 72.4 0
113 Yes 60 44.0 0
114 Yes 70 72.1 0
115 No 39 39.8 0
116 Yes 58 61.6 0
117 Yes 75 60.4 0
118 Yes 74 42.8 0
119 Yes 65 41.1 1
120 Yes 69 68.6 0
121 Yes 72 66.8 ND
EEC grade 2 122 Yes 69 64.5 2
123 Yes 74 50.7 0
124 Yes 64 25.2 2
125 Yes 65 53.8 0
126 No 47 69.5 1
127 Yes 55 5.4 0
128 Yes 67 65.9 0
129 Yes 61 33.1 0
130 Yes 81 63.6 0
131 Yes 84 64.7 1
EEC grade 3 132 Yes 86 36.0 1
133 Yes 54 23.8 0
134 Yes 79 50.0 ND
Abbreviation: ND, not determined. IHC scores include the following: 0, general absence of staining; 1, global weak staining; and 2, global
moderate staining.
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Figure 2. Methylation onOX2R locus in normal endometrium, EEC and cell lines. A, The sequence of exon 1 is presented with open arrows to indicate the
exon’s limits. CpG sites are numbered as appearing in the methylation patterns below. Horizontal arrows indicate the position of primers used for proximal and
distal PCR amplification. B and C, Representative methylation patterns of control and EEC cases. Each numbered column represents a CpG site and every row
represents a unique allele. Blue, red, and white squares, respectively, represent unmethylated, methylated, or undetermined CpG sites. The pattern in panel B
showsmostly unmethylated alleles in control endometrium (control 15), whereas EEC patient 119 in panel C shows intense methylation, which is maximal in
CpG sites 10–13 from the proximal portion. D, Methylation pattern ofOX2R exon 1 inMFE 280, ECC-1, and Ishikawa cells. In MFE 280, hypermethylated as well
as completely unmethylated clones are observed. In ECC-1 cells, the intense methylation pattern is recorded. In Ishikawa cells, methylated CpG sites are
concentrated at positions 11 and 12 from the proximal portion. RT-PCR for OX2R (E) andWestern blot (F) using anti-OX2R antibody for the 3 endometrial cell
lines. Only MFE 280 showed strong signals in E and F. For ECC-1 and Ishikawa cells, absent or very weak signals are recorded. Loading controls are given by
GAPDH RT-PCR (E) andWestern blot (F). G, Representative experiment showing the values (percentage of control) ofWST1 tests performedwith cell cultures
(ECC-1, MFE280, and Ishikawa) induced for 48 hours with graded concentrations of OX A and OX B. Orexins have no effect on cell proliferation. H,
Representative caspase-3/7 assays performedwith cell cultures (ECC-1, MFE280, and Ishikawa) induced for 48 hours with graded concentrations of OX A and
OX B. The values expressed in the percentage of noninduced controls show no effect of both orexins on apoptosis.
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receptors have been recently shown to have a broader role
in peripheral organs and in cancer. Many aspects of their
physiological roles are probably still to be uncovered.
We described here the localization of OX2R protein in
the epithelial compartment of normal endometrium dur-
ing the whole menstrual cycle and in
menopausal conditions. In EEC,
65.6% of 32 tumoral samples inves-
tigated were devoid of OX2R stain-
ing either completely or with mini-
mal focal labeling. Additionally,
hypermethylation of the first exon of
OX2Rwas demonstrated in EEC by
comparison with normal endome-
trium (median methylation percent-
age of 48.85% and 5.85%, res-
pectively). Comparisons between
methylation categories for the 3
grades of EEC in Figure 3G showed
similar methylation for grades 1 and
2 and a tendency toward lower per-
centages of the partially methylated
and hypermethylated categories for
grade 3, although this has to be con-
firmed on a larger number of clinical
samples. Similar observations re-
porting reducedmethylation rates in
advanced tumor stages have already
been done as, for example, in colo-
rectal cancer, in which O6-methyl-
guanine DNA methyltransferase
(MGMT) hypermethylation is more
intense in T1/T2 carcinomas than in
themore advanced T3/T4 stages (24).
TheMGMTprotein has then been re-
ported to be reexpressed in colon ad-
enocarcinomas (25), whereas it was
absent in MGMT-methylated adeno-
mas (26) from which carcinomas are
supposed to derive.
This is the first time that epige-
netic regulation is identified for
OX2R. Its genomic locus was re-
cently studied and revealed the pres-
ence of 3 nontranslated 5 exons and
theuseof alternativepromoters (27).
Here in vitro studies using cell lines
allowed the establishment of a cor-
relation between the methylation of
the first exon and the lack of gene
expression. The methylation of first
exons have indeed been recently
identified as major gene-silencing
events (28). InECC-1 cells, an intensemethylationof exon
1was correlatedwith the absence of signal inRT-PCRand
inOX2R immunoblotting. In Ishikawa cells, weakOX2R
transcription and protein expression was associated with
Figure 3. Quantitative methylation of OX2R first exon. A, Percentages of methylation for cancer
(n  34) and controls (n  18) samples. B, EEC patients (n  34): plotting of methylation
percentages and IHC scores showing the absence of correlation between them. C–G, Allocation
of OX2R bisulfite sequencing clones to the 3 methylations categories in controls (C; n  18) and
EEC grade 1 (D; n  21), grade 2 (E; n  10), grade 3 (F; n  3). G, Mean values for controls
and EEC of all 3 grades are displayed. In panel C, clones are mostly unmethylated. In panels D
and E, most of the samples show a high proportion of hypermethylated clones, which tends to
be lower in panel F for grade 3 EEC.
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sparsemethylation except aroundCpGsites 11and12 in the
proximal zone. In the MFE280 cells, for which a moderate
OX2Rexpressionisdetected,bothcompletelyunmethylated
and methylated clones were identified making the locus
hemizygous and permissive for OX2R expression. Unfortu-
nately, no nucleotide polymorphism could be found in the
sequenced fragments, and it was not possible to establish
whether theobservedheterogeneousmethylationwouldseg-
regate together with paternal and maternal alleles. This ob-
servation is interesting because it affects MFE280, a poorly
differentiated cell line. This could be related to the tendency
to lowermethylation density observed in grade 3 EEC.Het-
erogeneousmethylationappears tobe frequent in thehuman
genomeand is not always connected togene imprinting (29).
TheOX2R gene has not been reported to be imprinted, al-
though in a recent computational study (30), it was included
in a list of imprinted gene candidates.
By contrast, in vivo, no clear correlation could be
established between the methylation percentages and
the IHC scores evaluated on tumoral tissues (Figure 3B).
However, the samples with lower methylation levels
(50%) had a mean IHC score higher than samples
with high (50%) methylation levels (0.50 vs 0.29).
This failure to reach statistical significance for the cor-
relation could stem from either the low number of sam-
ples of highest tumor grade or the sampling method
applied. Indeed, the material used for DNA extraction
and the methylation study comes from a different part
of the tumor than the one used for OX2R IHC. In agree-
ment with our hypothesis, data from Faquin et al (31)
and Feng et al (32) also showed substantial heteroge-
neity in EEC.
In our study, the bisulfite sequencing after bacterial
cloning allowed the quantification of methylation at the
level of individual alleles later allocated into 3methylation
categories. This approach is particularly necessary when
analyzing heterogeneous material as tumoral samples
(33). The identification of OX2R methylation in EEC
could be prolonged by the establishment of an OX2R-
based test applicable in clinical diagnostic situations, us-
ing a methylation-specific PCR technology on endome-
trial tissue obtained by curettage as starting material.
WST1 proliferation assays in the presence ofOXAand
OX B or the caspase-3/7 tests did not show any difference
compared with controls, demonstrating the absence of
orexin-induced apoptosis. This result was obtained for the 3
cell lines including MFE280 with demonstrated expression
ofOX2R. An alternative explanation could be that the level
of expressionofOX2R inMFE280cellswouldbe too lowto
trigger orexin-induced apoptosis. In other cancermodels ex-
pressing OX2R, such an apoptosis has been reported in a
pancreatic rat cell line (34), whereas for adrenocortical ad-
enoma cells, a stimulation of growth and cortisol secretion
was described upon orexin induction (35). Thus, in the con-
text of endometrial cancer, the direct implication of OX2R
in the control of cell proliferation is not established and the
epigenetic OX2R down-regulation reported here may im-
pact cancer cells by other means that have yet to be uncov-
ered.DeCarvalho et al (36) recently studied themethylation
of promoter regions that were necessary for cancer cell sur-
vival. Intriguingly, no classical tumor suppressor gene was
evidenced by their screening, which identified many cell sig-
naling molecules, notably several G protein-coupled recep-
tors, leading the authors to conclude that the role of GPRCs
in tumor progression was probably underestimated. In this
study theOX2R silencing by DNA methylation might cer-
tainly be considered on the same line.
In the normal endometrium, the physiological role of
OX2Rand theorexinergic systemalso remains tobebetter
understood. Very recently the presence of OX A and OX
Bwas established in theporcine endometrium (37),which,
if confirmed in human tissues, could suggest an autocrine/
paracrine interaction of the orexins with OX2R as fore-
seen in the male genital tract (7).
In conclusion, theOX2Rwas shown tobe present in nor-
mal endometrium,whereas in EEC, a frequentOX2R loss is
associated with the frequent hypermethylation of its first
exon. Themethylation intensities are similar in grades 1 and
2 EEC and tend to regress in grade 3 clinical samples, al-
thoughmore grade 3 caseswould be required to confirm the
tendency. Heterogeneous methylation with the presence of
completely methylated and unmethylated alleles was also
observed on the MFE280 cell line characterized by poor
differentiation.
Table 3. Global and Detailed Methylation Evaluation in Controls and EEC of All Grades
Controls
(n  18)
All Grades Cancer
(n  34)
P
Value
Global methylation, % 5.85 (4.05–7.70) 48.85 (34.15–65.30) a
Detailed distribution of clones
Unmethylated (20%) 0.9348 (0.8254–0.9479) 0.2944 (0.1232–0.5040) a
Partially methylated (from 20% to 80%) 0.0652 (0.0521–0.1623) 0.4063 (0.2971–0.6181) a
Hypermethylated (80%) 0.0 (0.0–0.0) 0.1585 (0.0729–0.3750) a
Median values (25th and 75th percentile) are given. P values were calculated using the Mann-Whitney test.
a P  .0001.
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